YARW (Yarrow Bioscience) EBITDA per Share: $ (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

YARW Yarrow Bioscience Inc YARW
8 GF Score
Price $32.99
View Full Analysis

What is Yarrow Bioscience EBITDA per Share?

Yarrow Bioscience YARW +8.34% 8 EBITDA per Share is $ as of Dec. 2025. GuruFocus rates YARW with a GF Score™ of 8/100.

Yarrow Bioscience's EBITDA per Share for the six months ended in Dec. 2025 was $0.00. Yarrow Bioscience does not have enough years/quarters to calculate its EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Yarrow Bioscience's EBITDA per Share or its related term are showing as below:

YARW's 3-Year EBITDA Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 14.95
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

Yarrow Bioscience's EBITDA for the six months ended in Dec. 2025 was $0.00 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.


Yarrow Bioscience  (NAS:YARW) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Yarrow Bioscience EBITDA per Share Related Terms


Yarrow Bioscience EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Yarrow Bioscience's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yarrow Bioscience EBITDA per Share Chart

Yarrow Bioscience Annual Data
Trend Dec25
EBITDA per Share
0.00

Yarrow Bioscience Semi-Annual Data
Dec25
EBITDA per Share 0.00
YARW
8GF Score
Yarrow Bioscience Inc YARW
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Yarrow Bioscience EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Yarrow Bioscience's EBITDA per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA per Share(A: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=0/0
=N/A

Yarrow Bioscience's EBITDA per Share for the quarter that ended in Dec. 2025 is calculated as

EBITDA per Share(Q: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=0/0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of $ mean?
Yarrow Bioscience (YARW) has a EBITDA per Share of $ as of Dec. 2025. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Yarrow Bioscience and its competitors.
Is Yarrow Bioscience's EBITDA per Share too high?
Yarrow Bioscience's current EBITDA per Share is $. Overall, Yarrow Bioscience has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Yarrow Bioscience's EBITDA per Share compare to ?
Yarrow Bioscience's EBITDA per Share of $ can be compared against companies in the Biotechnology industry. The industry median EBITDA per Share is 14.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Biotechnology company?
The median EBITDA per Share among Biotechnology companies is 14.95, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Yarrow Bioscience and its competitors. For the Biotechnology industry, the median EBITDA per Share is 14.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yarrow Bioscience's current EBITDA per Share is $. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yarrow Bioscience stock overvalued right now?
Yarrow Bioscience (YARW) has a current EBITDA per Share of $. The current EBITDA per Share is $. Yarrow Bioscience's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Yarrow Bioscience (YARW), the current EBITDA per Share is $ as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yarrow Bioscience Business Description

Comparable Companies
Address 251 Little Falls Drive, County of New Castle, City of Wilmington, DE, USA, 19808
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
8GF Score

Get the complete analysis for YARW

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.99
Price